A Systematic Review of the Efficacy and Safety Experience Reported for Sorafenib in Advanced Renal Cell Carcinoma (RCC) in the Post-Approval Setting
Author:
Publisher
Public Library of Science (PLoS)
Subject
Multidisciplinary
Reference108 articles.
1. Sorafenib in advanced clear-cell renal-cell carcinoma;B Escudier;N Engl J Med,2007
2. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings;J Beck;Ann Oncol,2011
3. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America;WM Stadler;Cancer,2010
4. Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group;A Tafreshi;Asia Pac J Clin Oncol,2014
5. A large open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma;J Beck;Eur J Cancer Suppl,2007
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Emerging applications of anti-angiogenic nanomaterials in oncotherapy;Journal of Controlled Release;2023-12
2. Physicochemical and bacteriological quality and safety of packaged drinking water in Ouagadougou, Burkina Faso;Water Supply;2023-09-27
3. Synergistic anti-tumour activity of sorafenib in combination with pegylated resveratrol is mediated by Akt/mTOR/p70S6k-4EBP-1 and c-Raf7MEK/ERK signaling pathways;Heliyon;2023-08
4. Development and validation of a UPLC-MS/MS method for simultaneous detection of doxorubicin and sorafenib in plasma: Application to pharmacokinetic studies in rats;Saudi Pharmaceutical Journal;2023-07
5. Dose Intensity in Real-World Patients With Metastatic Renal Cell Carcinoma Taking Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors;Clinical Genitourinary Cancer;2023-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3